Castleview Partners LLC Sells 11,554 Shares of Bristol Myers Squibb Company $BMY

Castleview Partners LLC reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 13.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,988 shares of the biopharmaceutical company’s stock after selling 11,554 shares during the quarter. Bristol Myers Squibb accounts for 2.3% of Castleview Partners LLC’s portfolio, making the stock its 7th largest position. Castleview Partners LLC’s holdings in Bristol Myers Squibb were worth $4,487,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. waypoint wealth counsel acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth about $1,194,000. Life Cycle Investment Partners Ltd bought a new stake in Bristol Myers Squibb during the fourth quarter worth about $34,406,000. Axxcess Wealth Management LLC boosted its position in Bristol Myers Squibb by 27.4% during the fourth quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock valued at $5,322,000 after purchasing an additional 21,196 shares during the last quarter. Daytona Street Capital LLC acquired a new position in Bristol Myers Squibb during the fourth quarter valued at approximately $1,362,000. Finally, Pensionfund Sabic bought a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $1,845,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bank of America lowered its price target slightly to $66 from $67 but kept a Buy rating, signaling continued upside potential for Bristol Myers Squibb. Benzinga
• Positive Sentiment: Bristol Myers Squibb’s addition to defensive and value-defensive Russell indices could broaden demand from index-tracking and conservative institutional investors. Yahoo Finance
• Positive Sentiment: The company’s QUILS lung cancer detection program is expanding into new states, reinforcing its reputation in oncology and public-health initiatives. Yahoo Finance

Bristol Myers Squibb Stock Performance

Shares of BMY stock traded down $0.41 during trading on Friday, reaching $57.53. 11,202,444 shares of the company’s stock were exchanged, compared to its average volume of 12,071,738. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The firm’s fifty day moving average price is $56.83 and its 200-day moving average price is $57.62. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The stock has a market capitalization of $117.49 billion, a PE ratio of 16.16, a PEG ratio of 0.16 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same quarter last year, the firm posted $1.80 EPS. The company’s quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. Bristol Myers Squibb’s payout ratio is presently 70.79%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on BMY shares. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $54.00 price target on shares of Bristol Myers Squibb in a research report on Monday, July 6th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 2nd. Finally, Guggenheim reissued a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $61.25.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.